Sida 1 från 24 resultat
Nowadays, more and more patients are receiving anticancer treatment by mouth. In this context, the development of oral chemotherapy represents a challenge to our health system as it means adapting the hospital's organization and making it safer to manage patients who are becoming autonomous and
Multiple Myeloma (MM) is a molecularly heterogeneous disease with a high degree of genomic instability. Despite improvements in event-free survival and overall survival with the use of autologous stem cell transplantation and novel agents, MM remains an incurable disease (1,2). The best induction
Study Design (Methodology):
This is a 2-part, international, multi-center, open-label study of salvage treatment with tinostamustine conditioning followed by ASCT in patients with relapsed/ refractory multiple myeloma (MM). (ASCT is defined as salvage if the patient had already received a prior ASCT
Background:
- Multiple myeloma (MM) is a malignancy of plasma cells.
- MM is nearly always incurable.
- T cells can be genetically modified to express chimeric antigen receptors (CARs) that specifically target malignancy-associated antigens.
- Autologous T cells genetically modified to express CARs
Phase I Study Design
• Phase I will follow a 3+3 dose escalation design to determine the RPTD of ixazomib in combination with ONC201 and Dexamethasone.
The dose escalation rules for the phase I portion of the study are as follows, escalating in cohorts of 3 patients per dose level including a
Clinical Background
Bone metastasis give rise to major complications that lead to significant morbidity and impairment of life quality. The most common primary for bone metastasis is prostate, lung and breast carcinoma. These three have the highest cancer incidence in the USA with up to 85%
Indication:
This study will include subjects that have relapsed and refractory multiple myeloma (RRMM) after treatment with at least 3 prior antimyeloma therapies, including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD®) or after development of double-refractoriness to a both a PI
Background
Chronic cold agglutinin disease (CAD) is mediated by monoclonal cold-reactive autoantibodies that bind to erythrocyte surface antigens, causing hemagglutination and complement-mediated hemolysis. Anemia is severe in one-third of patients (hemoglobin level 8.0 g/dL or lower). Cold-induced
BACKGROUND:
- Multiple myeloma (MM) is a malignancy of plasma cells.
- MM is nearly always incurable.
- T cells can be genetically modified to express chimeric antigen receptors (CARs) that specifically target malignancy-associated antigens.
- Autologous T cells genetically modified to express CARs
Multiple myeloma (MM) is one of the most common hematological diseases and besides the option of an allogeneic stem cell transplantation remains incurable.
Although autologous stem cell transplantation and new compounds such as bortezomib, thalidomide and lenalidomide have been implemented,
After the screening procedures confirm that the participant is eligible to participate in the research study:
Because no one knows which of the study options is best, the participant will be "randomized" into one of the study groups:
- G-CSF with meloxicam
- G-CSF with placebo (pills with no
PRIMARY ENDPOINTS:
Phase I • Determination of the MTD of the combination therapy
Phase II:
• Response rate (CR+PR)
SECONDARY ENDPOINTS:
- Overall Response Rate (ORR)
- Progression Free Survival (PFS)
- Time to Progression (TTP)
- Time to next therapy
A total of 56 patients may be enrolled in this